Pharmaceutical composition containing the combination ofaronia melanocarpa

EP4395803A4Pending Publication Date: 2024-11-27ISTINYE UNIVERSITESI
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
EP2022937684
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-21
Filing Date
2022-11-24
Publication Date
2024-11-27

AI Technical Summary

Technical Problem

Existing synthetic anti-ulcer drugs for gastrointestinal diseases, such as stomach ulcers caused by NSAIDs, have significant side effects like diarrhea, itching, skin rash, and dizziness, prompting the need for non-toxic, natural alternatives with curative, therapeutic, and preventive effects.

Method used

A pharmaceutical composition combining lyophilized Aronia melanocarpa fruit juice or extract with peritrophin matrix proteins isolated from Lucilia sericata fly larvae, mixed in a 1:1 weight ratio, providing antioxidant, anti-inflammatory, and wound-healing properties to address gastrointestinal issues.

Benefits of technology

The composition significantly reduces ulceration and inflammation markers, enhances antioxidant levels, and accelerates healing, offering a safer and more effective treatment for gastrointestinal diseases with improved stability and daily preventive benefits.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition comprising Peritrophin and Aronia melanocarpa fruit, juice, or extract for the treatment of gastrointestinal diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PHARMACEUTICAL COMPOSITION CONTAINING THE COMBINATION OF ARONIA MELANOCARPA FRUIT AND PERITROPHIN FOUND IN LARVAL

[0002] SECRETION

[0003] Technical Field of the Invention

[0004] The present invention relates to a pharmaceutical composition containing Peritrophin and Aronia melanocarpa for the treatment of gastrointestinal diseases.

[0005] State of the Art (Prior Art)

[0006] Many synthetic anti-ulcer drugs (e.g misoprostol) have been developed that can be used specifically to prevent or treat stomach ulcers, one of the gastrointestinal diseases caused by nonsteroidal anti-inflammatory drugs (NSAIDs). However, these drugs have limitations since they have many side effects such as diarrhea, itching, skin rash, and dizziness. Therefore, there is a need for non-toxic, natural anti-ulcer formulations derived from biological sources.

[0007] Many synthetic anti-ulcer drugs (e.g, misoprostol) have been developed that can be used specifically to prevent or treat stomach ulcers caused by NSAIDs. However, these drugs have limitations since they have many side effects such as diarrhea, itching, skin rash, and dizziness. Therefore, there is interest again in non-toxic, natural anti-ulcer formulations derived from biological sources.

[0008] Natural polyphenols have been reported to play various beneficial roles in the gastrointestinal tract. Among these roles, so far, in addition to antispasmodic, anti-inflammatory, cytoprotective, anti secretory, antimicrobial, anti-cholinergic, anti-secretory, anti diarrheal, anti- ulcerative, and antioxidant properties, it shows that it prevents gastric ulcer through different mechanisms such as suppression of gastrin and histamine, regulation of VEGF. In addition, the therapeutic effects of various conventional and complementary medicines on peptic ulcers are also related to their polyphenol content. Polyphenols are known to have a protective and therapeutic potential in peptic ulcer by upregulating tissue growth factors and prostaglandins; and this structure has biological effects such as increasing NO derived from endothelial nitric oxide synthase, suppressing oxidative mucosal damage, enhancing antioxidant performance, antacid and anti -secretory activity, increasing endogenous mucosal defense agents, and blocking gastroduodenal inflammation and ulceration.

[0009] There is a need for natural compounds or drugs for effective healing and treatment of these diseases despite the development of a number of drugs for the prevention and treatment of gastrointestinal diseases.

[0010] Brief Description and Objects of the Invention

[0011] The primary object of the present invention is to prepare a composition consisting of natural components that have both curative, therapeutic, and preventive effects for gastrointestinal system problems.

[0012] The object of the present invention is to obtain a composition comprising aronia berries, preferably its juice, known for their peritrophin matrix proteins isolated purely from the intestines of Lucilia sericata fly larvae, and known for their anticarcinogenic, antidiabetic, anti oxi dative, liver, and heart health protective effects.

[0013] Another object of the present invention is to lyophilize the composition comprising aronia berries, preferably its juice, known for their peritrophin matrix proteins isolated purely from the intestines of Lucilia sericata fly larvae, and known for their anticarcinogenic, antidiabetic, anti oxi dative, liver, and heart health protective effects, for longer stability.

[0014] The peritrophic matrix (PM) is a structure that acts as a barrier between the contents of the midgut lumen and the epithelial cells, which plays a protective role against mechanical damage, pathogens, toxins, and other harmful substances, and that is secreted by the intestines of insects that also controls the ultrafiltration properties of the intestine. This layer of cell-free material consists of chitin, proteins, and proteoglycans. The porosity of PM controls the division of digestive enzymes and food, and also protects underlying epithelial cells from viral and parasite invasion.

[0015] In addition to the studies carried out with the juice or extracts of Aronia fruit, the fruit with the highest ORAC value, it has been shown by means of the present invention that the antioxidant levels are increased at least twofold thanks to the aronia components. It also improved the ulceration rate and inflammation markers in the range of 40-54%. Peritrophin matrix proteins obtained from Lucilia sericata larvae, which are used to accelerate the healing process of wounds that do not heal under larval debridement treatment under normal conditions have been shown to improve on mechanical damage in the range of 35-42%. As a result of oral use of both products at a ratio of 1 : 1 by weight, it has been shown that it provides an improvement in the range of 47-62% in the healing of the ulceration area due to both antioxidative effect and anti-inflammatory effect thereof.

[0016] The composition of the present invention is obtained by mixing peritrophin proteins and aronia berry, extract or juice in powder form, preferably at a ratio of 1 : 1 by weight. Aronia fruit, which is one of the fruits with a very high antioxidant effect by means of the peritrophin proteins, a component of the larval secretion, effects of which on wound healing have been proven, both supports digestion and heals possible ulcer-induced wounds with its synergetic effects as a result of combining the lyophilized forms of this fruit extract or juice.

[0017] By using the two products in the composition of the present invention in the recommended lyophilized form, facilitating the digestion process, protection against mechanical damage, pathogens, toxins and other harmful substances, anti-inflammatory properties; and antioxidative properties by means of its quercetin component and wound healing accelerating properties by means of its gallocatechin component are seen together, and especially ulcer- related digestive system problems are prevented.

[0018] The product, which is brought into lyophilized form, can also reduce reactive oxygen species and increase the antioxidant level due to antioxidative properties thereof, and it can even be used daily in the field of preventive medicine with its antidiabetic, heart-liver protective, antihyperlipidemic effects.

[0019] Detailed Description of the Invention

[0020] The present invention relates to a pharmaceutical composition comprising peritrophin and Aronia melanocarpa in lyophilized form for the treatment of gastrointestinal diseases such as ulcer, gastritis, reflux, colitis. The mass ratio of Peritrophin and Aronia melanocarpa in the pharmaceutical composition is 1 : 1.

[0021] In an exemplary embodiment, the composition comprises 30-70% by weight of Peritrophin and 30-70% by weight of Aronia melanocarpa, preferably, the composition comprises 50% by weight of Peritrophin and 50% by weight of Aronia melanocarpa. The fruit, juice, or extract of Aronia melanocarpa is preferably used, and more preferably, its juice is used.

[0022] In general, the preparation method of the composition of the present invention comprises the process steps of; • Obtaining peritrophin matrix proteins from larval secretion,

[0023] • Lyophilizing the obtained peritrophin matrix proteins,

[0024] • Mixing Aronia melanocarpa fruit, juice, or extract in powder form and peritrophin matrix proteins in powder form, and

[0025] • preferably dissolving the mixture in water.

[0026] In the preparation method of the composition of the present invention, in the first step, pupae are provided first. The pupae provided are placed in cages and chicken livers are left in the cages of the flies that become adults to lay eggs on certain days. Petri dishes containing liver are collected from the cages after 5-6 hours for larvae harvesting, the eggs here are separated and sterilized and transferred to sterile falcon tubes, and 30-40 ml of 0.05% sodium hypochlorite is added therein. Then, it is shaken in the shaker for 10-15 minutes at a speed range of 200-300 rpm, after the eggs settle to the bottom, the upper liquid is drained and again, 30-40 ml of 5% formaldehyde is added to the eggs and the tubes are put back into the shaker under the same conditions. Eggs in formaldehyde are emptied into a filter, and 500 ml of sterile FTS is placed on it at the same time with the help of a motor for drawing liquid, and the liquid is drawn off. Eggs are planted on agar media containing chicken livers and incubated overnight in an oven set at 3 C, and the larvae in the medium taken the next day are kept in the same medium at room temperature overnight.

[0027] In order to obtain secretion from the second and third instar larvae, the incubated larvae are counted and collected in a beaker, although it varies according to the total number of larvae, the required amount of dELO is calculated, dELO amount calculated in total is put on the larvae in 4 equal amounts every hour, and after 4 hours, the secretion is transferred to sterile glass tubes.

[0028] The larval secretion obtained for purification of peritrophin matrix proteins from the obtained secretion is purified from possible bacterial contamination by passing through 0.22 pm filters, and sterile larval secretion is purified by ultrafiltration and high-pressure liquid chromatography processes to purify peritrophin matrix proteins. The purified peritrophin matrix proteins are brought into powder form with a lyophilizer.

[0029] In the second stage, Aronia melanocarpa fruit is provided, the stem parts of the fruit are removed, and mechanically purified by washing in water. The cleaned Aronia melanocarpa fruit is completely crushed with a chopper system or a homogenizer and converted into liquid form. It is filtered with the help of a strainer to remove solid particles, and the liquid part obtained is purified from possible bacterial contamination by passing through 0.22 pm filters. Sterile Aronia melanocarpa liquid is brought into powder form with a lyophilizer. Lyophilized forms of Peritrophin and Aronia melanocarpa fruit are prepared in a ratio of 1 : 1. For solvent purposes, dHzO is made ready for use in glass bottles. The lyophilized combination is prepared in powder form integrated into the cap of the glass bottle, thus, when the user buys this product, the lyophilized combination on the cap is transferred into the glass bottle, and the product is shaken and made ready for use. The product is stored in the refrigerator.

Claims

CLAIMS1. Pharmaceutical composition for the treatment of gastrointestinal diseases; characterized by comprising lyophilized Peritrophin proteins and lyophilized Aronia melanocarpa.

2. Pharmaceutical composition according to Claim 1, characterized by comprising fruit, extract, or juice of Aronia melanocarpa.

3. Pharmaceutical composition according to Claim 1, characterized in that, the ratio of peritrophin and Aronia melanocarpa is 1 : 1 by mass.

4. Pharmaceutical composition according to Claim 1, characterized by comprising 30- 70% by weight Peritrophin and 30-70% by weight Aronia melanocarpa.

5. Pharmaceutical composition according to Claim 4, characterized by comprising 50% by weight Peritrophin and 50% by weight Aronia melanocarpa.

6. Preparation method of the composition according to Claim 1, characterized by comprising the process steps of;• Obtaining peritrophin matrix proteins from larval secretion,• Lyophilizing the obtained peritrophin matrix proteins,• Mixing Aronia melanocarpa in powder form and peritrophin matrix proteins in powder form.

7. Method according to Claim 6, characterized in that, Aronia melanocarpa in powder form and peritrophin matrix proteins in powder form are soluble in water.

8. Method according to Claim 6 or 7, characterized in that, Aronia melanocarpa fruit, juice, or extract thereof is used.

9. Pharmaceutical composition according to any one of claims 1-5 for use as a drug.

10. Pharmaceutical composition according to Claim 9 for use as a drug in the treatment of gastrointestinal diseases.

11. Use according to Claim 10, characterized in that, gastrointestinal disease is ulcer, reflux, gastritis, or colitis

Citation Information

Patent Citations

  • Use of Aronia extract e.g. for the prevention or therapeutic treatment of bacterial disease, mycotic disease and / or inflammatory disease

    DE102005046474A1